HIF1A and cancer: These mutations may lead to an increase in mTOR activity and thus HIF-1α protein synthesis, which may render cancer cells resistant to anti-HIF-1α therapies that affect upstream regulators of HIF-1α synthesis, such as those targeting receptor tyrosine kinases.